Pfizer’s Art Of The Deal
PositiveFinancial Markets

Pfizer's recent agreement with Trump to lower drug prices is generating positive buzz among investors, even though it may not significantly affect the company's profits. This deal alleviates regulatory uncertainties that have been a concern for the pharmaceutical giant, allowing it to focus on its core business. The move is seen as a strategic win for Pfizer, showcasing its adaptability in a challenging market.
— Curated by the World Pulse Now AI Editorial System